ImmunoGenesis

Executive Summary

ImmunoGenesis is a private, Houston-based biopharmaceutical company pioneering small-molecule therapeutics to convert immunologically 'cold' tumors into 'hot' ones, thereby expanding the benefits of immunotherapy to the majority of cancer patients who currently do not respond. Founded in 2016, the company leverages cutting-edge academic discoveries in tumor immunology to design drugs that modulate the tumor microenvironment and enhance anti-tumor immunity. ImmunoGenesis is currently advancing its lead program through Phase 1/2 clinical trials, having demonstrated early signals of immune activation and tumor regression in preclinical models. The company's approach targets key pathways that suppress immune responses in cold tumors, such as STING agonists or A2A receptor antagonists, though specific mechanisms remain undisclosed. With a seasoned management team and a focus on high-unmet-need indications, ImmunoGenesis is positioned to address a significant gap in oncology: bringing effective immunotherapy to patients with non-responsive tumors. The company's progress will hinge on generating compelling clinical data that validates its platform and differentiates its small-molecule drugs from antibody-based immunotherapies.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 initial efficacy and safety data readout for lead program in cold tumors40% success
• Q2 2027IND filing for second-generation STING agonist or next pipeline candidate60% success
• H1 2027Potential strategic partnership or licensing deal with major pharma30% success